

Functional domains of the ATPase inhibitor protein from bovine heart mitochondria

Franco Zanotti^{a,b}, Gabriella Raho^a, Rita Vuolo^a, Antonio Gaballo^a, Francesco Papa^a, Sergio Papa^{a,*}

^aDepartment of Medical Biochemistry and Biology, University of Bari, Piazza G. Cesare-Policlinico, 70125 Bari, Italy

^bCentre for the Study of Mitochondria and Energy Metabolism, Consiglio Nazionale delle Ricerche, University of Bari, Bari, Italy

Received 7 August 2000; revised 5 September 2000; accepted 6 September 2000

Edited by Matti Saraste

Abstract A study is presented of the activity and temperature dependence of the ATPase inhibitor protein (IF₁) from bovine heart mitochondria and of synthetic partial IF₁ peptides. The results show that the IF₁-(42–58) peptide is the most potent inhibitory domain of IF₁. © 2000 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.

Key words: F₁F₀ ATP synthase; Inhibitor protein of mitochondrial ATPase; Synthetic ATPase inhibitor peptide

1. Introduction

The F₁F₀ ATP synthase of coupling membranes catalyzes ATP synthesis driven by the protonmotive force (PMF) generated by respiratory or photoredox systems [1]. In mitochondria, wasteful ATP hydrolysis by the F₁F₀ complex is specifically inhibited by the ATPase inhibitor protein, IF₁ [2–4].

IF₁ associates reversibly in a 1:1 stoichiometry with F₁F₀, from which it is displaced by the PMF, thus IF₁ has no significant effect on ATP synthesis [2]. The ΔpH component of PMF, in particular the matrix pH, on which side IF₁ is associated with the complex, is the critical factor for its binding and inhibitory activity [2,5,6]. In our laboratory it has been found that IF₁ also inhibits passive proton conduction by the F₁F₀ complex [6].

Bovine IF₁ is a basic protein of 84 amino acids [7] and is present in other eukaryotes [8,9]. The amino acid sequence is well conserved in these proteins. Studies from various laboratories have attempted to identify the functional domain(s) of the IF₁ protein. Harris et al. [10,11] first suggested that an α-helical rod encompassing residues 22–79 in bovine heart IF₁ protein represents the functional segment (Fig. 1). Stout et al. [12] showed that the synthetic peptide with the sequence Phe22–Lys46 in bovine IF₁ inhibits the ATPase activity in the soluble F₁. Papa et al. [13] and van Raij et al. [14] found, however, that this peptide has no significant effect on the ATPase activity of the F₁F₀ complex.

Studies with proteolytic fragments of IF₁ [15] and genetic deletions in the recombinant protein [14] indicated that the last 10–20 residues of the C-terminus are not directly essential for the inhibitory activity. The same seems to apply to the first 13 residues of the N-terminus [14]. van Raij et al. [14] concluded from their studies with recombinant products of bovine IF₁ that the minimal inhibitory sequence consists of residues 14–47. Papa et al. [13] have, on the other hand, shown that the synthetic peptide with the Phe42–Lys58 sequence of bovine IF₁ is equally effective, as the natural complete IF₁, in inhibiting the ATPase activity of both the F₁F₀ complex in the membrane and of soluble F₁. The 42–58 segment has at positions 48, 49, 55 and 56 four histidines. Histidine chemical modification [5,6], site directed mutagenesis of His49 [16] and chemical substitution of His48, 49, 55, 56 or of Lys46, 47, 58 in the synthetic 42–58 peptide [13] have shown that these residues are directly responsible for the activity and pH dependence of IF₁.

In this paper a study is presented on the activity and temperature dependence of IF₁ and synthetic IF₁ segments. The results clearly establish that the Phe42–Lys58 segment of IF₁ is the most potent inhibitory domain of IF₁.

2. Materials and methods

2.1. Materials

CM C-25 Sephadex, ATP, phosphoenolpyruvate (PEP), NADH, pyruvate kinase, lactate dehydrogenase, were from Boehringer; chemicals for synthesis and sequence were obtained from Applied Biosystem; thioanisole and ethanediol from Fluka; *tert*-butylether from Carlo Erba. All other chemical reagents were of analytical grade.

2.2. Preparations

Inside-out vesicles of the inner mitochondrial membrane were obtained by exposure of isolated bovine heart mitochondria [17] to ultrasonic energy in the presence of 4 mM EDTA at pH 8.5 (ESMP) or in the presence of 1 mM MgATP (MgATP-SMP) [18]. Sequential treatment of ESMP with Sephadex chromatography produced particles from which IF₁ was removed (SMP) [19]. IF₁ was isolated from MgATP-SMP according to [20]. Recombinant IF₁ was a generous gift of Professor John Walker (Medical Research Council, Cambridge, UK). The protein concentration was determined by the Lowry method [13].

2.3. Assays

The ATP hydrolase activity was measured with an ATP-regenerating system as in [14,21].

2.4. Synthesis of peptides

Synthetic peptides with conserved or mutated sequences of IF₁ were obtained by a standard solid-phase method with a fully automatic peptide synthesizer (model 431A of Applied Biosystem) using the Fmoc chemistry [22]. After synthesis the peptides were deprotected

*Corresponding author. Fax: (39)-80-5478429.
E-mail: papabchm@cimedoc.uniba.it

Abbreviations: IF₁, inhibitor protein of mitochondrial ATPase; ESMP, submitochondrial particles prepared in the presence of EDTA; SMP, submitochondrial particles deprived of IF₁; F₀, membrane integral sector of the H⁺-ATP synthase; F₁, catalytic sector of the H⁺-ATP synthase

by incubating for 2 h at room temperature in 83% trifluoroacetic acid, 4% thioanisol, 2% ethanediol and 6% crystalline phenol. After cleavage, the peptides were precipitated by 10 vol. of anhydrous *tert*-butyl-ether, pelleted, washed four additional times with ether and lyophilized. The purity of the synthetic peptides was checked by reverse-phase high performance liquid chromatography on a Perkin Elmer C-8/10 column with a linear gradient of acetonitrile in 0.1% aqueous trifluoroacetic acid. The sequence of the synthetic peptides was verified by amino acid analysis performed with a fully automatic peptide sequencer (model 473A of Applied Biosystems). The repetitive yield of sequence analysis was higher than 90%. The solubility in water of the wild and mutant IF₁-(42–58) peptide and of IF₁-(22–46) peptide was > 10 mg/ml. The protein concentration of solutions of IF₁ and IF₁ synthetic peptides, prepared on a w/v basis, was checked using the Lowry method against a standard solution of bovine albumin [13].

3. Results

Fig. 2 shows the titrations of the inhibitory effects of the purified native IF₁, recombinant IF₁ and IF₁ synthetic polypeptide segments on the ATPase activity of 'inside-out' sub-mitochondrial particles from bovine heart deprived of the endogenous IF₁ (SMP), measured at 21 and 37°C. It can be observed that the inhibitory affinity of the active peptides increases greatly with temperature. At both temperatures the natural and the recombinant IF₁ proteins exhibited the same inhibitory affinity. The synthetic peptide with the Phe42–Lys58 sequence of the bovine IF₁ showed, both at 21 and 37°C, an inhibitory affinity three times higher than the natural and the recombinant IF₁. Replacement of the four histidines at positions 48, 49, 55 and 56 or of the three lysines at positions 46, 47 and 58 in the IF₁-(42–58) peptide practically abolished its inhibitory activity at both temperatures. The IF₁-(Phe22–Lys46) peptide, which exhibits inhibitory activity on the purified F₁ sector [12], did not exert any significant inhibitory activity on the ATPase activity of the native F₁F₀ complex in SMP (see also [13,14]). It should be noted that,




Fig. 1. The amino acid sequence of the bovine heart IF₁. The solid box contains the IF₁-(42–58) peptide, the dotted box the IF₁-(14–47) peptide [14].

like the complete IF₁, the IF₁-(42–58) peptide caused permanent, stable inhibition of the ATPase activity of SMP (Fig. 3). The *I*₅₀ values for natural and recombinant IF₁, when measured in the present study at 37°C, are exactly the same as those obtained at the same temperature by van Raaij et al. for the recombinant IF₁ [14]. Thus, the *I*₅₀ values for the synthetic IF₁ peptides we have synthesized can be directly compared with those obtained for the IF₁ segments used by these authors (see Section 4).

Fig. 4 illustrates the temperature dependence of the inhibitory activities of natural and recombinant IF₁ and of the synthetic IF₁-(42–58) peptide. The *I*₅₀ values of IF₁ and of IF₁-(42–58) peptide decreased as the temperature was increased from 21 to 37°C (Fig. 4). It can be noted that *I*₅₀ values of the IF₁-(42–58) peptide were, in the temperature range examined, always lower than the *I*₅₀ values of IF₁. The latter decreased, however, more steeply as the temperature increased. These results thus show that the IF₁-(42–58) peptide has an inhibitory affinity significantly higher and a binding energy lower than the complete IF₁.

4. Discussion

The *I*₅₀ values for inhibition of the ATPase activity of the F₁F₀ complex in inside-out vesicles of bovine heart inner mi-




Fig. 2. Titration at two temperatures of the inhibitory effect of natural IF₁, recombinant IF₁ and synthetic, conserved and mutant, IF₁ segments on ATPase activity in SMP. SMP (1 mg/ml) were incubated in a reaction mixture containing: 200 mM sucrose, 10 mM Tris/acetate, 1 mM K-EDTA, 6 mM MgCl₂, 1 mM MgATP, pH 6.7 in the presence of IF₁ or IF₁ partial peptides in the concentration range reported in the figure. The mixture was incubated at 21°C (a) or 37°C (b) for 10 min and then an aliquot of the suspension containing 50 μg particle protein was added to 1 ml of the ATPase assay mixture containing: 200 mM sucrose, 50 mM KCl, 5 mM MgCl₂, 10 U lactate dehydrogenase, 20 mM Tris/HCl, 0.1 mM NADH, 1 mM PEP, 4 U pyruvate kinase and 1 mM rotenone, pH 8.0. The ATPase activity, started by the addition of 1 mM MgATP, was followed by monitoring the oxidation of NADH at 340 nm at the temperature of 21°C (a) or 37°C (b). Submitochondrial particles deprived of IF₁ were incubated in the presence of: (□) natural IF₁; (▲) recombinant IF₁; (○) IF₁-(42–58) synthetic peptide; (△) IF₁-(22–46) synthetic peptide; (●) [Ala48,49,55,56]-IF₁-(42–58) synthetic peptide; (■) [Ala46,47,58]-IF₁-(42–58) synthetic peptide.

tochondrial membrane show that, compared to the complete IF₁ from the same source or produced by heterologous expression, the synthetic IF₁-(42–58) peptide, with an *I*₅₀ of 220 nM at 21°C and 9 nM at 37°C, is the most potent inhibitory IF₁ partial segment among all those so far tested in our [13] and other laboratories [14,23]. The inhibitory affinity of the IF₁-(42–58) peptide has, in fact, an inhibitory affinity for the ATPase activity of the F₁F₀ complex even higher than that of the complete IF₁. The inhibitory activity of the IF₁-(42–58) peptide is permanent, i.e. the peptide–F₁F₀ complex is as stable as that formed by the complete IF₁ (Fig. 3), exhibits the same pH dependence, with an optimum at a pH around 6.5 [13], and a marked temperature dependence as the complete IF₁. The marked enhancement with temperature of the inhibitory affinity of IF₁ for the ATP synthase, could play an important role in promoting effective inhibition of wasteful ATP hydrolysis, which, under conditions of respiratory deficiency, might be quite relevant at body temperatures around 37°C.

No equivalent data are available on the pH and temperature dependence of the inhibition of the ATPase activity of the F₁F₀ complex exerted by the partial IF₁ peptides tested by van Raaij et al. [14]. Of the various IF₁ peptides used by these authors, the IF₁ (10–47) synthetic peptide was reported to be the minimal effective inhibitory peptide. With an *I*₅₀ of 45 nM at 37°C and pH 6.5 it is, however, five-fold less active than the IF₁-(42–58) peptide. Furthermore, at difference with the IF₁-(42–58) peptide which produced a stable inhibition, the inhibition of the ATPase activity by the IF₁-(10–47) peptide was reported to decrease during the assay period, this indicating that the peptide–F₁F₀ complex was unstable [14]. Van Raaij et al. [14] have proposed that the four histidines in the 42–58 segment increase the stability of the IF₁–F₁F₀ complex. A truncated IF₁ peptide, missing up to 24 residues from the




Fig. 4. Temperature dependence of the inhibitory effect of natural IF₁, recombinant IF₁ and synthetic IF₁ (42–58) peptide on the ATP hydrolase activity of SMP. The *I*₅₀ for the inhibition of the ATP hydrolase activity of SMP were obtained by incubating the particles with (□) natural IF₁, (▲) recombinant IF₁ and (○) IF₁-(42–58) synthetic peptide in a range of concentrations between 0 and 2 μM for 10 min at the temperatures reported in the figure. The ATPase activity was then started and measured as reported in the legend to Fig. 2. For other details, see the legend to Fig. 2 and Section 2.

C-terminus, i.e. the IF₁-(1–60) peptide containing the IF₁-(42–58) segment, exhibited practically the same inhibitory affinity and stability as the complete IF₁ and the IF₁-(42–58) peptide [14]. It seems possible to conclude that the 42–58 segment represents the primary critical domain of IF₁. The inability of the IF₁-(23–84) peptide [14,23] and the IF₁-(44–84) peptide [14] to inhibit the ATPase activity of the F₁F₀ complex, could result from an occlusion of the active 42–58 segment by the C-terminal region in the absence of the N-terminus. The IF₁-(42–58) peptide contains the residues K46 and K47 which are shared by the 10–47 peptide, the H49, which has been found to be responsible for the pH dependence of the inhibitory activity of IF₁ [16], three additional histidines and one more lysine, which are likely to increase the stability of the inhibitor–F₁F₀ complex. The pH dependence of the inhibitory activity of IF₁ and the IF₁-(42–58) peptide with optimum around 6.5 [13], indicates that positive charges on protonated histidine imidazole groups in addition to those of the lysines are involved in the binding of IF₁ to negatively charged dicarboxylic residues in the F₁F₀ complex. The sequence K46K47H48 could specifically interact with the last three residues of the conserved DELSEED sequence [24] at position β 394–400 in the C-terminal domain of the β subunit at the bottom of the F₁ spherical body facing the F₀ sector in the membrane [24,25].

Recently, Cabezon et al. [26] have proposed that protonation of His49 induces the IF₁ to acquire a dimeric active state which inhibits the ATPase activity of dimeric F₁F₀ complexes [27]. Deprotonation of His49 results, according to these authors [26] in the formation of an inactive IF₁ tetramer. If the dimer–tetramer interconversion of IF₁, observed for the isolated IF₁, also takes place in the interaction of IF₁ with the F₁F₀ complex in the membrane, this interconversion could represent an additional consequence of the histidine protonation in the IF₁-(42–58) domain.

Acknowledgements: This work was supported by grants from the National Project on Bioenergetics and Biomembranes, 1999 of the Italian Ministry for the University and Scientific and Technological Research




Fig. 3. Inhibitory effect of recombinant IF₁ and IF₁-(42–58) synthetic peptide on the ATP hydrolase activity of SMP. SMP (1 mg/ml) were incubated in the same reaction mixture reported in the legend to Fig. 1 at 37°C in the absence (a) or in the presence of 0.075 μM recombinant IF₁ (b), or in the presence of 0.025 μM IF₁-(42–58) synthetic peptide (c). For other details see Section 2 and the legend to Fig. 2.

(MURST), and the finalized Project for Biotechnology of the Italian Research Council (CNR, Rome) Project No. 99.00430.PF49. A.G. is supported by a research grant from the University of Bari within the CEE operative program 94/99 'Ricerca, Sviluppo Tecnologico ed Alta Formazione'.

References

- [1] Boyer, P.D. (1997) *Annu. Rev. Biochem.* 66, 717–749.
- [2] Harris, D.A. and Das, A.M. (1991) *Biochem. J.* 280, 561–573.
- [3] Walker, J.E. (1994) *Curr. Opin. Struct. Biol.* 4, 912–918.
- [4] Green, D.W. and Grover, G.J. (2000) *Biochim. Biophys. Acta* 1458, 343–355.
- [5] Panchenko, M.V. and Vinogradov, A.D. (1985) *FEBS Lett.* 184, 226–230.
- [6] Guerrieri, F., Zanotti, F., Che, Y.W., Scarfò, R. and Papa, S. (1987) *Biochim. Biophys. Acta* 892, 284–293.
- [7] Pullman, M.E. and Monroy, G.C. (1963) *J. Biol. Chem.* 238, 3762–3769.
- [8] Cintron, N.M. and Pedersen, P.L. (1979) *J. Biol. Chem.* 254, 3439–3443.
- [9] Hashimoto, T., Negawa, Y. and Tagawa, K. (1981) *J. Biochem.* 90, 1151–1157.
- [10] Harris, D.A. (1984) in: (Papa, S., Altendorf, K., Ernster, L. and Packer, L., Eds.), *H⁺-ATPase: Structure, Function, Biogenesis*, pp. 387–395. Adriatica Editrice, Bari.
- [11] Jackson, P.J. and Harris, D.A. (1988) *FEBS Lett.* 229, 224–228.
- [12] Stout, J.S., Partridge, B.E., Dibbern, D.A. and Schuster, S.M. (1993) *Biochemistry* 32, 7496–7502.
- [13] Papa, S., Zanotti, F., Cocco, T., Perrucci, C., Candita, C. and Minuto, M. (1996) *Eur. J. Biochem.* 240, 461–467.
- [14] van Raaij, M.J., Orris, G.L., Montgomery, M.G., Runswick, M.J., Fearnley, I.M., Skehel, J.M. and Walker, J.E. (1996) *Biochemistry* 35, 15618–15625.
- [15] Hashimoto, T., Yamamoto, Y., Yoshida, Y. and Tagawa, K. (1995) *J. Biochem.* 117, 641–647.
- [16] Schnizer, R., Van Heeke, G., Amaturio, D. and Schuster, S.M. (1996) *Biochim. Biophys. Acta* 1292, 241–248.
- [17] Low, H. and Vallin, J. (1963) *Biochim. Biophys. Acta* 69, 361–374.
- [18] Lee, C.P. and Ernster, L. (1968) *Eur. J. Biochem.* 3, 391–400.
- [19] Racker, E. and Horstmann, L.L. (1967) *J. Biol. Chem.* 242, 2547–2551.
- [20] Kanner, B.I., Serrano, R., Kandrach, M.A. and Racker, E. (1976) *Biochem. Biophys. Res. Commun.* 69, 1050–1056.
- [21] Guerrieri, F., Kopecky, J. and Zanotti, F. (1989) in: (Tager, J., M., Azzi, A., Papa, S. and Guerrieri, F., Eds.), *Organelles of Eukaryotic Cells*, pp. 197–208. Plenum Press, New York.
- [22] Kent, S.B.H. (1988) *Annu. Rev. Biochem.* 57, 957–989.
- [23] Harris, D.A. (1997) *Biochim. Biophys. Acta* 1320, 8–16.
- [24] Runswick, M.J. and Walker, J.E. (1983) *J. Biol. Chem.* 258, 3081–3089.
- [25] Abrahams, J.P., Leslie, A.G.W., Lutter, R. and Walker, J.E. (1994) *Nature* 370, 621–628.
- [26] Cabezon, E., Butler, P.J.G., Runswick, M.J. and Walker, J.E. (2000) *J. Biol. Chem.*, in press.
- [27] Arnold, I., Pfeiffer, K., Neupert, W., Stuart, R.A. and Shagger, H. (1998) *EMBO J.* 17, 7170–7178.